We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in the Offing for Ventas Stock This Earnings Season?
Read MoreHide Full Article
Key Takeaways
Ventas is set to report Q3 2026 results Oct. 27, with revenues seen rising 18.3% and FFO per share 11.4%.
Senior housing occupancy and long-term leases are expected to support rental revenues and quarterly growth.
Triple-net rental income is projected to fall to $125.2M, while high interest expenses may weigh on results.
Ventas, Inc. (VTR - Free Report) is scheduled to report third-quarter 2026 results on Oct. 27, after market close. The quarterly results are likely to show year-over-year growth in revenues and normalized funds from operations (FFO) per share.
In the last reported quarter, this Chicago-based healthcare real estate investment trust (REIT) delivered a normalized FFO per share of 97 cents, beating the Zacks Consensus Estimate by a cent. The quarterly results reflected a year-over-year increase in same-store cash net operating income, driven by strong performance in the senior housing operating portfolio (SHOP) and outpatient medical research (OM&R) portfolio.
Ventas’ normalized FFO per share surpassed the Zacks Consensus Estimate in three of the preceding four quarters and met once, with the average beat being 1.37%. The graph below depicts this surprising history:
In the third quarter of 2026, Ventas’ SHOP is likely to have benefited from an aging U.S. population and a rise in healthcare expenditure by this age cohort, which is generally higher than that of the average population. With the segment witnessing positive net move-ins, occupancy is expected to have remained high.
A well-diversified tenant base with long-term leases is expected to have contributed well to stable rental revenue generation, boosting the top line.
However, the triple-net leased properties are likely to have been affected during the to-be-reported quarter. Further, high interest expenses are expected to have cast a pall on the company’s performance to some extent.
VTR’s Q3 Projections
The Zacks Consensus Estimate for third-quarter 2026 revenues is currently pegged at $1.76 billion, implying an 18.3% increase from the prior-year quarter’s reported figure.
The Zacks Consensus Estimate for third-quarter resident fees and services is pegged at $1.39 billion, suggesting an increase from $1.09 billion reported in the year-ago period.
The consensus mark for OM&R portfolio rental income for the third quarter is pegged at $229.5 million, indicating an increase from $226.2 million reported in the year-ago period.
However, the Zacks Consensus Estimate for third-quarter triple-net leased properties' rental income is pegged at $125.2 million, suggesting a decrease from $160.1 million reported in the year-ago period.
Ventas’ activities during the soon-to-be-reported quarter have been inadequate to gain analysts’ confidence. The Zacks Consensus Estimate for third-quarter FFO per share has decreased a cent to 98 cents over the past week. However, the figure implies an increase of 11.4% from the year-ago quarter’s reported number.
What Our Quantitative Model Predicts for VTR
Our proven model predicts a likely surprise in terms of FFO per share for Ventas this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an FFO beat, which is the case here.
Ventas currently has an Earnings ESP of +0.70% and a Zacks Rank #3. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Stocks That Warrant a Look
Here are two stocks from the broader REIT industry — BXP, Inc. (BXP - Free Report) and American Healthcare REIT (AHR - Free Report) — that you may want to consider, as our model shows that these have the right combination of elements to report a surprise this quarter.
BXP, which is scheduled to report third-quarter 2026 results on Oct. 27, has an Earnings ESP of +0.04% and a Zacks Rank #3 at present.
American Healthcare REIT is slated to report third-quarter 2026 results on Nov. 5. AHR has an Earnings ESP of +0.60% and a Zacks Rank of #2 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Note: Anything related to earnings presented in this write-up represents funds from operations (FFO) — a widely used metric to gauge the performance of REITs.
View the Zacks #1 Rank List
Image: Bigstock
What's in the Offing for Ventas Stock This Earnings Season?
Key Takeaways
Ventas, Inc. (VTR - Free Report) is scheduled to report third-quarter 2026 results on Oct. 27, after market close. The quarterly results are likely to show year-over-year growth in revenues and normalized funds from operations (FFO) per share.
In the last reported quarter, this Chicago-based healthcare real estate investment trust (REIT) delivered a normalized FFO per share of 97 cents, beating the Zacks Consensus Estimate by a cent. The quarterly results reflected a year-over-year increase in same-store cash net operating income, driven by strong performance in the senior housing operating portfolio (SHOP) and outpatient medical research (OM&R) portfolio.
Ventas’ normalized FFO per share surpassed the Zacks Consensus Estimate in three of the preceding four quarters and met once, with the average beat being 1.37%. The graph below depicts this surprising history:
Ventas, Inc. Price and EPS Surprise
Ventas, Inc. price-eps-surprise | Ventas, Inc. Quote
Factors at Play for VTR
In the third quarter of 2026, Ventas’ SHOP is likely to have benefited from an aging U.S. population and a rise in healthcare expenditure by this age cohort, which is generally higher than that of the average population. With the segment witnessing positive net move-ins, occupancy is expected to have remained high.
A well-diversified tenant base with long-term leases is expected to have contributed well to stable rental revenue generation, boosting the top line.
However, the triple-net leased properties are likely to have been affected during the to-be-reported quarter. Further, high interest expenses are expected to have cast a pall on the company’s performance to some extent.
VTR’s Q3 Projections
The Zacks Consensus Estimate for third-quarter 2026 revenues is currently pegged at $1.76 billion, implying an 18.3% increase from the prior-year quarter’s reported figure.
The Zacks Consensus Estimate for third-quarter resident fees and services is pegged at $1.39 billion, suggesting an increase from $1.09 billion reported in the year-ago period.
The consensus mark for OM&R portfolio rental income for the third quarter is pegged at $229.5 million, indicating an increase from $226.2 million reported in the year-ago period.
However, the Zacks Consensus Estimate for third-quarter triple-net leased properties' rental income is pegged at $125.2 million, suggesting a decrease from $160.1 million reported in the year-ago period.
Ventas’ activities during the soon-to-be-reported quarter have been inadequate to gain analysts’ confidence. The Zacks Consensus Estimate for third-quarter FFO per share has decreased a cent to 98 cents over the past week. However, the figure implies an increase of 11.4% from the year-ago quarter’s reported number.
What Our Quantitative Model Predicts for VTR
Our proven model predicts a likely surprise in terms of FFO per share for Ventas this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an FFO beat, which is the case here.
Ventas currently has an Earnings ESP of +0.70% and a Zacks Rank #3. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Stocks That Warrant a Look
Here are two stocks from the broader REIT industry — BXP, Inc. (BXP - Free Report) and American Healthcare REIT (AHR - Free Report) — that you may want to consider, as our model shows that these have the right combination of elements to report a surprise this quarter.
BXP, which is scheduled to report third-quarter 2026 results on Oct. 27, has an Earnings ESP of +0.04% and a Zacks Rank #3 at present.
American Healthcare REIT is slated to report third-quarter 2026 results on Nov. 5. AHR has an Earnings ESP of +0.60% and a Zacks Rank of #2 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Note: Anything related to earnings presented in this write-up represents funds from operations (FFO) — a widely used metric to gauge the performance of REITs.